Definium Therapeutics’ (DFTX) Outperform Rating Reiterated at Royal Bank Of Canada

Royal Bank Of Canada reissued their outperform rating on shares of Definium Therapeutics (NASDAQ:DFTX) in a research report released on Friday morning,Benzinga reports. Royal Bank Of Canada currently has a $66.00 price objective on the stock.

A number of other analysts have also issued reports on the company. Wall Street Zen lowered Definium Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th. Robert W. Baird raised their price objective on Definium Therapeutics from $57.00 to $75.00 and gave the company an “outperform” rating in a report on Thursday, August 13th. Wells Fargo & Company lifted their target price on shares of Definium Therapeutics from $68.00 to $72.00 and gave the stock an “overweight” rating in a research note on Thursday, August 13th. Citigroup reaffirmed a “buy” rating on shares of Definium Therapeutics in a report on Monday, June 22nd. Finally, Stifel Nicolaus increased their target price on shares of Definium Therapeutics from $30.00 to $60.00 and gave the company a “buy” rating in a research report on Wednesday, July 8th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Definium Therapeutics presently has an average rating of “Buy” and a consensus target price of $63.00.

Definium Therapeutics Price Performance

DFTX stock opened at $38.89 on Friday. Definium Therapeutics has a 52 week low of $8.77 and a 52 week high of $49.70. The company has a quick ratio of 6.95, a current ratio of 6.95 and a debt-to-equity ratio of 0.04. The firm has a 50-day simple moving average of $43.01 and a 200-day simple moving average of $30.33. The stock has a market capitalization of $5.23 billion, a P/E ratio of -11.34 and a beta of 2.23.

Definium Therapeutics (NASDAQ:DFTX) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($1.44) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.89). Equities analysts forecast that Definium Therapeutics will post -3.02 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CFO Brandi Roberts sold 3,013 shares of Definium Therapeutics stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $45.03, for a total transaction of $135,675.39. Following the transaction, the chief financial officer owned 209,487 shares in the company, valued at $9,433,199.61. The trade was a 1.42% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Matthew T. Wiley sold 2,867 shares of the business’s stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $45.03, for a total transaction of $129,101.01. Following the transaction, the insider directly owned 174,633 shares in the company, valued at approximately $7,863,723.99. The trade was a 1.62% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 67,119 shares of company stock valued at $2,887,496 in the last quarter. Corporate insiders own 2.40% of the company’s stock.

Hedge Funds Weigh In On Definium Therapeutics

A number of institutional investors have recently bought and sold shares of DFTX. Royal Bank of Canada boosted its holdings in Definium Therapeutics by 10.4% in the 1st quarter. Royal Bank of Canada now owns 65,237 shares of the company’s stock valued at $382,000 after purchasing an additional 6,148 shares during the last quarter. Creative Planning raised its position in shares of Definium Therapeutics by 2.6% during the 2nd quarter. Creative Planning now owns 66,097 shares of the company’s stock valued at $429,000 after buying an additional 1,655 shares during the period. JPMorgan Chase & Co. raised its position in shares of Definium Therapeutics by 5.1% during the 2nd quarter. JPMorgan Chase & Co. now owns 48,487 shares of the company’s stock valued at $315,000 after buying an additional 2,342 shares during the period. Rhumbline Advisers lifted its holdings in Definium Therapeutics by 6.3% in the second quarter. Rhumbline Advisers now owns 115,296 shares of the company’s stock valued at $748,000 after acquiring an additional 6,839 shares during the last quarter. Finally, Russell Investments Group Ltd. lifted its holdings in Definium Therapeutics by 110.4% in the second quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock valued at $25,000 after acquiring an additional 2,003 shares during the last quarter. 27.91% of the stock is owned by hedge funds and other institutional investors.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.